The state of Illinois currently has 463 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318
Recruiting
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Rush - Copley Medical Center, Aurora, Illinois +43 locations
Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Register for Updates
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT05207709
Recruiting
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Carle Cancer Center, Urbana, Illinois
Conditions: Metastatic Breast Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Saint Anthony's Health, Alton, Illinois +83 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT05710380
Recruiting
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/15/2023
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
Register for Updates
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT00005095
Recruiting
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.
Gender:
Female
Ages:
Between 18 years and 80 years
Trial Updated:
06/13/2023
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois
Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Register for Updates
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
NCT02634645
Recruiting
A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/09/2023
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Barrett's Esophagus, Esophageal Cancer
Register for Updates
Patient Navigation 2.0
NCT04234646
Recruiting
This study evaluates whether a "Patient Navigation 2.0 Checklist" intervention is effective in addressing patients' social determinants of health and recommended cancer-related screenings, behavioral counseling, and immunizations.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/08/2023
Locations: Northwestern, Chicago, Illinois
Conditions: Cancer
Register for Updates
SurvivorLink: Scalability of an Electronic Personal Health Record
NCT03543852
Recruiting
Previous research suggests that children and adolescents with cancer are at heightened risk of late effects that can occur months or years after cancer treatment, yet little is known about programs that increase their return for follow-up cancer care and late effects surveillance. This study will evaluate the impact of an electronic personal health record and education system, SurvivorLink, for pediatric cancer survivors and their caregivers. The researchers will develop a standardized intervent... Read More
Gender:
All
Ages:
All
Trial Updated:
06/06/2023
Locations: University of Chicago Medicine Comer Children's Hospital, Chicago, Illinois
Conditions: Childhood Cancer
Register for Updates
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
NCT04315701
Recruiting
This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or has spread regionally (regionally advanced), and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2023
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer, Stage III Skin Cancer
Register for Updates
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629
Recruiting
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More
Gender:
Male
Ages:
21 years and above
Trial Updated:
05/04/2023
Locations: University of Illinois at Chicago, Chicago, Illinois +5 locations
Conditions: Prostate Cancer
Register for Updates
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-012 - University of Chicago, Chicago, Illinois
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
NCT03238976
Recruiting
Patients will be randomly assigned to one of two groups: the group exposed to NS, or the standard care group exposed to supportive dialogue. Patients assigned to the former group will be exposed to continuous NS throughout the CNB procedure.
Gender:
Female
Ages:
21 years and above
Trial Updated:
04/26/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates